Education
About Us
Working with TipRanks
Follow Us
Resverlogix Corp. (TSE:RVX)
:RVX
RVX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.10
Previous CloseN/A
Volume1.00K
Average Volume (3M)47.20K
Market Cap
C$11.37M
Enterprise ValueN/A
Total Cash (Recent Filing)C$95.00K
Total Debt (Recent Filing)$6.77M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Aug 19, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 04, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding284,263,900
10 Day Avg. Volume40,231
30 Day Avg. Volume47,205
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Resverlogix News
PremiumCompany Announcements
Resverlogix Showcases Apabetalone’s Heart Health Benefits
PremiumCompany Announcements
Resverlogix Secures Shareholder Approval and Debenture Extension
PremiumCompany Announcements
Resverlogix Amends Debenture Terms Amidst Therapy Development
PremiumCompany Announcements
Resverlogix Reschedules Shareholder MeetingOptions Prices
Currently, No data available
---
Ownership Overview
0.68% Insiders
―
Mutual Funds
― Other Institutional Investors
99.32% Public Companies and
Individual Investors
RVX FAQ
What was Resverlogix Corp.’s price range in the past 12 months?
Resverlogix Corp. lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Resverlogix Corp.’s market cap?
Resverlogix Corp.’s market cap is C$11.37M.
When is Resverlogix Corp.’s upcoming earnings report date?
Resverlogix Corp.’s upcoming earnings report date is Aug 19, 2025 which is in 69 days.
How were Resverlogix Corp.’s earnings last quarter?
Currently, no data Available
Is Resverlogix Corp. overvalued?
According to Wall Street analysts Resverlogix Corp.’s price is currently Overvalued.
Does Resverlogix Corp. pay dividends?
Resverlogix Corp. pays a Notavailable dividend of C$0.4 which represents an annual dividend yield of N/A. See more information on Resverlogix Corp. dividends here
What is Resverlogix Corp.’s EPS estimate?
Resverlogix Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. have?
Resverlogix Corp. has 284,263,900 shares outstanding.
What happened to Resverlogix Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Resverlogix Corp.?
Currently, no hedge funds are holding shares in TSE:RVX
Company Description
Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Technical Analysis
Kane Biotech
―
Britannia Life Sciences Inc
―
Tetra Bio-Pharma
―
BetterLife Pharma
―
BioVaxys Technology
―